Intellia Thera CS (NTLA)

$11.42 0.00 (N/A)
Market Cap 1.23B
Revenue (ttm) 57.88M
Net Income (ttm) -519.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -896.72%
Debt to Equity Ratio 0.00
Volume 3,346,400
Avg Vol 4,520,186
Day's Range N/A - N/A
Shares Out 107.35M
Stochastic %K 34%
Beta 2.28
Analysts Strong Sell
Price Target $31.83

Company Profile

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune dis...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 285 6200
Address:
40 Erie Street, Suite 130, Cambridge, United States
ebodonicus
ebodonicus Sep. 13 at 9:33 PM
$NTLA I thought Blackrock was previously one of the big institutional investors for all of my CRISPR stocks. As of recently, I no longer see them when I look at institutional ownership. (I don’t really know what I’m doing, but I try.) Does anybody know what I’m talking about? Were they invested before? Did they bail ? Am I missing something? Any insight would be appreciated.
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 12 at 9:48 PM
Enter: $NTLA OCT 17 2025 $12 CALLS Buy in Price: $0.69 - $0.85 Take Profit: $0.77 Stop Bleeding: $0.61 ROI Potential: 12% Exit Within: 57 Minutes https://moneygroup.us/alerts
0 · Reply
APman
APman Sep. 12 at 1:54 PM
$NTLA
0 · Reply
Dkll303
Dkll303 Sep. 12 at 11:04 AM
$QURE and the failures continue here as well as at $NTLA
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 11 at 10:19 PM
Enter: $NTLA OCT 17 2025 $12 CALLS Buy in Price: $0.85 - $1.00 Take Profit: $1.12 Stop Bleeding: $0.75 ROI Potential: 32% Exit Within: 39 Minutes https://moneygroup.us/alerts
0 · Reply
jeojackson
jeojackson Sep. 11 at 9:34 PM
$NTLA Underperforming all of my crisper stocks. And this is my top pick.
0 · Reply
MMillionaireWookie
MMillionaireWookie Sep. 11 at 8:37 PM
$NTLA blah blah blah
1 · Reply
Dandelo
Dandelo Sep. 11 at 7:48 PM
$NTLA Entire sector going up. Let's see how long MMs can keep this beach ball underwater.
0 · Reply
WhysoSerious93
WhysoSerious93 Sep. 11 at 3:23 PM
$NTLA can't hold any gains
0 · Reply
APman
APman Sep. 11 at 2:51 PM
$RXRX $BEAM $NTLA $TEM Looks like Cathie Wood day today!
1 · Reply
Latest News on NTLA
Why big players are pouring millions in THIS biotech stock

Sep 1, 2025, 8:43 AM EDT - 13 days ago

Why big players are pouring millions in THIS biotech stock

Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)

Aug 15, 2025, 12:24 PM EDT - 4 weeks ago

Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)

Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 8:17 PM EDT - 5 weeks ago

Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Aug 1, 2025, 7:30 AM EDT - 6 weeks ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

Jul 31, 2025, 7:30 AM EDT - 6 weeks ago

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

Jul 30, 2025, 11:07 AM EDT - 6 weeks ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT CABA NGNE QURE RCKT

With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy'

Jul 18, 2025, 8:00 AM EDT - 2 months ago

With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy'

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Jun 15, 2025, 10:45 AM EDT - 3 months ago

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course

May 29, 2025, 11:25 AM EDT - 3 months ago

Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course

I Missed The Quantum Rally - I Won't Miss The Next One

May 20, 2025, 5:47 AM EDT - 4 months ago

I Missed The Quantum Rally - I Won't Miss The Next One

AMSC AUTL CAPR CLPT EDIT VANI VERV

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

May 18, 2025, 7:25 AM EDT - 4 months ago

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

Intellia Therapeutics, Inc. (NTLA) BofA Securities 2025 Healthcare Conference (Transcript)

May 14, 2025, 1:57 PM EDT - 4 months ago

Intellia Therapeutics, Inc. (NTLA) BofA Securities 2025 Healthcare Conference (Transcript)

Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade)

May 12, 2025, 9:07 AM EDT - 4 months ago

Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade)

Intellia Therapeutics, Inc. (NTLA) Q1 2025 Earnings Call Transcript

May 8, 2025, 11:37 AM EDT - 4 months ago

Intellia Therapeutics, Inc. (NTLA) Q1 2025 Earnings Call Transcript

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts

May 5, 2025, 4:44 AM EDT - 4 months ago

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts

CRSP

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

May 1, 2025, 7:30 AM EDT - 4 months ago

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Apr 23, 2025, 9:50 AM EDT - 5 months ago

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

Apr 14, 2025, 10:58 AM EDT - 5 months ago

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

Apr 10, 2025, 10:40 AM EDT - 5 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

Apr 9, 2025, 10:49 AM EDT - 5 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit – NTLA

Apr 3, 2025, 1:03 PM EDT - 5 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit – NTLA

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Apr 3, 2025, 7:30 AM EDT - 5 months ago

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication

Mar 28, 2025, 6:24 AM EDT - 6 months ago

Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Mar 26, 2025, 7:30 AM EDT - 6 months ago

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Intellia Therapeutics, Inc. (NTLA) Barclays 27th Annual Global Healthcare Conference (Transcript)

Mar 11, 2025, 5:43 PM EDT - 6 months ago

Intellia Therapeutics, Inc. (NTLA) Barclays 27th Annual Global Healthcare Conference (Transcript)

Intellia Therapeutics, Inc. (NTLA) Leerink 2025 Global Biopharma Conference (Transcript)

Mar 10, 2025, 6:03 PM EDT - 6 months ago

Intellia Therapeutics, Inc. (NTLA) Leerink 2025 Global Biopharma Conference (Transcript)

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit - NTLA

Mar 6, 2025, 5:45 AM EST - 6 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit - NTLA

Intellia Trades Lower After Q4 Results As Clinical Progress Fails To Impress

Mar 2, 2025, 9:30 AM EST - 7 months ago

Intellia Trades Lower After Q4 Results As Clinical Progress Fails To Impress

ebodonicus
ebodonicus Sep. 13 at 9:33 PM
$NTLA I thought Blackrock was previously one of the big institutional investors for all of my CRISPR stocks. As of recently, I no longer see them when I look at institutional ownership. (I don’t really know what I’m doing, but I try.) Does anybody know what I’m talking about? Were they invested before? Did they bail ? Am I missing something? Any insight would be appreciated.
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 12 at 9:48 PM
Enter: $NTLA OCT 17 2025 $12 CALLS Buy in Price: $0.69 - $0.85 Take Profit: $0.77 Stop Bleeding: $0.61 ROI Potential: 12% Exit Within: 57 Minutes https://moneygroup.us/alerts
0 · Reply
APman
APman Sep. 12 at 1:54 PM
$NTLA
0 · Reply
Dkll303
Dkll303 Sep. 12 at 11:04 AM
$QURE and the failures continue here as well as at $NTLA
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 11 at 10:19 PM
Enter: $NTLA OCT 17 2025 $12 CALLS Buy in Price: $0.85 - $1.00 Take Profit: $1.12 Stop Bleeding: $0.75 ROI Potential: 32% Exit Within: 39 Minutes https://moneygroup.us/alerts
0 · Reply
jeojackson
jeojackson Sep. 11 at 9:34 PM
$NTLA Underperforming all of my crisper stocks. And this is my top pick.
0 · Reply
MMillionaireWookie
MMillionaireWookie Sep. 11 at 8:37 PM
$NTLA blah blah blah
1 · Reply
Dandelo
Dandelo Sep. 11 at 7:48 PM
$NTLA Entire sector going up. Let's see how long MMs can keep this beach ball underwater.
0 · Reply
WhysoSerious93
WhysoSerious93 Sep. 11 at 3:23 PM
$NTLA can't hold any gains
0 · Reply
APman
APman Sep. 11 at 2:51 PM
$RXRX $BEAM $NTLA $TEM Looks like Cathie Wood day today!
1 · Reply
PorkchopSquats
PorkchopSquats Sep. 11 at 2:09 PM
$NTLA Distinctly lagging the moves by BEAM, CRSP, and PRME. Technical indicators still weak, need to see a bit more punch before having confidence here again.
3 · Reply
APman
APman Sep. 11 at 1:58 PM
$NTLA
0 · Reply
free2dream
free2dream Sep. 11 at 1:39 PM
$XBI is there walls street elite who decides when this actually goes up ? $MRNA $SRPT $NTLA clearly all want to go up but the machines or the dickheads sitting behind the machines are holding this up
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 11 at 4:09 AM
Enter: $NTLA OCT 17 2025 $12 CALLS Buy in Price: $0.70 - $0.80 Take Profit: $0.79 Stop Bleeding: $0.62 ROI Potential: 13% Exit Within: 23 Minutes https://moneygroup.us/alerts
0 · Reply
Mcnulty_jimmy
Mcnulty_jimmy Sep. 10 at 9:39 PM
$NTLA $PRME Real ones know this is the right duo
3 · Reply
blueb22
blueb22 Sep. 10 at 7:47 PM
$BEAM $NTLA $SRPT $VKTX $KURA and many others with large short position -- Will crooks shorties and hedgies be able to keep their position open going into next week with 0.5% (or may be more) rate cut coming? (They will be burnt and running for cover if they do!) Also, rotation into good Biotechs which are undervalued is inevitable in next few days and weeks... Good Luck Longs 👍
0 · Reply
PorkchopSquats
PorkchopSquats Sep. 10 at 7:41 PM
$NTLA Got 🐑’d out of this while I was still above my cost average today. Looking bad rn.
0 · Reply
jeojackson
jeojackson Sep. 10 at 7:18 PM
$NTLA Fk!
0 · Reply
All4soun
All4soun Sep. 10 at 5:48 PM
$NTLA Yeah! Down, down. Fukin BS!
0 · Reply
APman
APman Sep. 10 at 5:44 PM
$NTLA Picked up 23k
0 · Reply
Turkeycock
Turkeycock Sep. 10 at 5:19 PM
$NTLA still adding
0 · Reply
free2dream
free2dream Sep. 10 at 1:35 PM
$XBI the market ignoring AI future in Biotech $MRNA $SRPT $NTLA
1 · Reply